ORKA
Oruka Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 27 ▼ Oruka Therapeutics announced a $500M underwritten public offering of…
- Apr 28 ▼ Oruka Therapeutics priced an upsized underwritten public offering of…
- Aug 9 ▲ A powerful institutional cluster emerged in Oruka Therapeutics (ORKA…
- Aug 10 ▲ Oruka Therapeutics reported Q2 2026 results in line with pre-revenue…
- Aug 28 ▼ Oruka Therapeutics' S-3 shelf registration (File No. 333-298488) bec…
- Oct 1 ▼ 1 insider sell $1.4M at $83.40
- Oct 12 to Oct 20 ▼ 3 days of insider sells: $2.0M by 3 insiders, avg $78.32
- Oct 25 FDA: Oruka Therapeutics to Host Conference Call to Report Week…
- Oct 25 Oruka Therapeutics will report Week 16 data for its lead candidate O…
- Oct 26 ▲ Oruka Therapeutics announced positive Week 16 results from its Phase…
- Nov 2 ▼ 1 insider sell $2.4M at $95.60
- Nov 12 ▼ 2 insiders sell $2.9M at $104.94
Signal stack
Where each data set points today.
- InsidersMIXED
5 insiders sold $8.7M. Excludes 6 subscriber-only trades.
- InstitutionsBULLISH
Q3 2026: 31 added (0 new), 13 trimmed or exited.
- AnalystsBULLISH
19 of 20 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +5.8% to 6.46M shares. 7.1 days to cover, ≈9.8% of shares.
- TrendUPTREND
17% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FRANKLIN TEMPLETON INC | ADD | $206.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | DOUBLED | $132.6M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | ADD | $69.1M |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | $38.3M |
| Pictet Asset Management Holding SA | TRIM | $33.5M |
| UBS Group AG | TRIM | $26.7M |
| Aberdeen Group plc | TRIM | $23.1M |
| Fisher Asset Management, LLC | DOUBLED | $18.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
20 analystsPrice is below the lowest target. Median implies +48%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 10, 2026 | BTIG REITERATE | Buy |
| Oct 27, 2026 | Guggenheim REITERATE | Buy |
| Oct 27, 2026 | Wedbush REITERATE | Outperform |
| Oct 19, 2026 | BTIG REITERATE | Buy |
| Sep 24, 2026 | Wedbush REITERATE | Outperform |
| Sep 24, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 16, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | EXERCISE | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | EXERCISE | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | SELL |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
36 filings · 4 press releases · 5 bullish · 5 bearish · 26 neutral- NEUTRAL SC 13GNov 16, 2026
T. Rowe Price Investment Management disclosed a 6.6% passive stake in Oruka Therapeutics as of September 30, 2026, with 4,392,166 shares. This is a new 13G filing from a major asset manager, indicating passive investment intent with no control-related purpose.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
RTW Investments, LP filed an amended Schedule 13G disclosing a 4.7% passive stake (3,139,030 shares) in Oruka Therapeutics as of September 30, 2026. The filing is an amendment to the initial 13G filed August 14, 2026, and the stake appears unchanged from the prior filing.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL CLUSTERNov 13, 2026
Two insiders at Oruka Therapeutics (ORKA) executed open-market sales totaling $173K on November…
The sales are immaterial in size and executed under pre-arranged 10b5-1 plans. No signal for stock direction. Monitor next earnings or pipeline catalyst for material insider activity.
- NEUTRAL CLUSTERNov 13, 2026
Two insiders at Oruka Therapeutics, including a director and the SVP of Finance, sold shares under…
Monitor for any material corporate developments or upcoming earnings that could explain the sales, but the small size and 10b5-1 plans suggest no immediate concern.
All ORKA filing & press-release reports (40)
- SC 13G reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- CLUSTER reportNov 13, 2026
- CLUSTER reportNov 13, 2026
- 144 reportNov 12, 2026
- 144 reportNov 12, 2026
- PRESS-RELEASE reportNov 9, 2026
- INST-CLUSTER reportNov 2, 2026
- 144 reportNov 2, 2026
- 8-K reportOct 26, 2026
- PRESS-RELEASE reportOct 25, 2026
- CLUSTER reportOct 20, 2026
- CLUSTER reportOct 15, 2026
- CLUSTER reportSep 21, 2026
- CLUSTER reportSep 15, 2026
- CLUSTER reportSep 1, 2026
- EFFECT reportAug 28, 2026
- CLUSTER reportAug 17, 2026
- PRESS-RELEASE reportAug 10, 2026
- 8-K reportAug 10, 2026
- INST-CLUSTER reportAug 9, 2026
- CLUSTER reportJul 15, 2026
- CLUSTER reportJul 1, 2026
- CLUSTER reportJun 22, 2026
- CLUSTER reportJun 15, 2026
- CLUSTER reportJun 15, 2026
- CLUSTER reportJun 15, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 1, 2026
- CLUSTER reportMay 22, 2026
- CLUSTER reportMay 18, 2026
- PRESS-RELEASE reportApr 28, 2026
- 424B5 reportApr 27, 2026
- PRESS-RELEASE reportApr 27, 2026
- 8-K reportApr 27, 2026
- DEFA14A reportApr 17, 2026
- 144 reportApr 15, 2026
- EFFECT reportApr 13, 2026
- CLUSTER reportMar 16, 2026
- PRESS-RELEASE reportMar 12, 2026